The effect of low-dose estrogen and progestogen on menopausal symptoms and urinary excretion of calcium.
The effects of low-dose estrogen and progestogen on menopausal symptoms were studied with Kuppermen score and urinary excretion of calcium as fasting morning urine Ca/Cr ratio in 69 perimenopausal women. The subjects were divided into 3 groups: amenorrhea less than 1 year (14 women); post menopause 1-3 years (19); and post menopause more than 3 years (36). Fasting urine Ca/Cr ratio in the post menopause 1-3 years group was 0.19 +/- 0.01, significantly higher than that (0.14-0.01) in the amenorrhea less than 1 year group and (0.11 +/- 0.006) the post menopause more than 3 years group. 18 women had 4 patterns of low-dose oral estrogen and progestogen: MPA 2 mg QOD, EE 5 micrograms QD, EE 5 micrograms QOD, and EE 5 micrograms and MPA 2 mg QOD. Each pattern was used in turn for 3 weeks, and discontinued for 2 weeks, then the next pattern started and so on. EE 5 micrograms and MPA 2 mg QOD alternately gave the best results both in improving symptoms and lowering urine Ca/Cr ratio. Seven women given intermittent large dose, namely, EE 50 micrograms every 10 days or premarin 2.5 mg every 7 days had symptoms relieved but inconsistent decrease of urine Ca/Cr ratio.
Lin
S Q
SQ
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing.
Ge
Q S
QS
Yao
F Y
FY
Feng
D D
DD
Wang
H L
HL
D000328:Adult; D002118:Calcium / Q000652:urine*; D003404:Creatinine / Q000652:urine; D015914:Estrogen Replacement Therapy; D004997:Ethinyl Estradiol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D017258:Medroxyprogesterone Acetate; D008593:Menopause / Q000652:urine; D008875:Middle Aged
D004997:Ethinyl Estradiol; D003404:Creatinine; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; D002118:Calcium